Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

1.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P.

PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016.

2.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment .

de Jong J, Skee D, Hellemans P, Jiao J, de Vries R, Swerts D, Lawitz E, Marbury T, Smith W, Sukbuntherng J, Mannaert E.

Leuk Lymphoma. 2016 Jun 7:1-10. [Epub ahead of print]

PMID:
27267254
3.

Clinical safety and performance of VIVIA: a novel home hemodialysis system.

Bernardo AA, Marbury TC, McFarlane PA, Pauly RP, Amdahl M, Demers J, Hutchcraft AM, Leypoldt JK, Minkus M, Muller M, Stallard R, Culleton BF.

Nephrol Dial Transplant. 2016 Apr 6. pii: gfw044. [Epub ahead of print]

PMID:
27190336
4.

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E.

J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527. [Epub ahead of print]

PMID:
26957110
5.

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.

Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin P.

Ther Drug Monit. 2016 Feb 27. [Epub ahead of print]

PMID:
26926668
6.

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.

Nguyen L, Holland J, Ramies D, Mamelok R, Benrimoh N, Ciric S, Marbury T, Preston RA, Heuman DM, Gavis E, Lacy S.

J Clin Pharmacol. 2016 Feb 11. doi: 10.1002/jcph.714. [Epub ahead of print]

PMID:
26865195
7.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Martin P, Oliver S, Gillen M, Marbury T, Millson D.

Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27.

PMID:
26519231
8.

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.

Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C.

J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22.

PMID:
26331581
9.

Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects.

Biswal S, Polus F, Pal P, Veldandi UK, Marbury TC, Perry R, Legangneux E.

Int J Clin Pharmacol Ther. 2015 Oct;53(10):855-65. doi: 10.5414/CP202369.

PMID:
26308174
10.

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.

Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M.

J Viral Hepat. 2015 Dec;22(12):1011-9. doi: 10.1111/jvh.12435. Epub 2015 Jul 16.

PMID:
26183611
11.

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.

Khatri A, Menon RM, Marbury TC, Lawitz EJ, Podsadecki TJ, Mullally VM, Ding B, Awni WM, Bernstein BM, Dutta S.

J Hepatol. 2015 Oct;63(4):805-12. doi: 10.1016/j.jhep.2015.05.029. Epub 2015 Jun 10.

PMID:
26070406
12.

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

Adkison KK, Gan J, Elko-Simms L, Gardner S, Dumont E, Jones LS, Saunders J, Marbury T, Smith W, Berg J, Galloway C, Stump PJ.

J Clin Pharmacol. 2015 Sep;55(9):1042-50. doi: 10.1002/jcph.512. Epub 2015 May 25.

PMID:
25857714
13.

Clinical improvement in psoriasis with specific targeting of interleukin-23.

Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, Kittler H, Blumenschein WM, McClanahan TK, Marbury T, Zachariae C, Xu D, Hou XS, Mehta A, Zandvliet AS, Montgomery D, van Aarle F, Khalilieh S.

Nature. 2015 May 14;521(7551):222-6. doi: 10.1038/nature14175. Epub 2015 Mar 9.

PMID:
25754330
14.

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E.

Clin Ther. 2015 Mar 1;37(3):610-628.e4. doi: 10.1016/j.clinthera.2014.12.013. Epub 2015 Feb 3.

PMID:
25659911
15.

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.

Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M.

Antivir Ther. 2015;20(5):535-43. doi: 10.3851/IMP2941. Epub 2015 Feb 5.

PMID:
25654812
16.

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS.

Thromb Haemost. 2015 Apr;113(4):719-27. doi: 10.1160/TH14-06-0547. Epub 2015 Jan 8.

PMID:
25566930
17.

Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.

Hu X, Seddighzadeh A, Stecher S, Zhu Y, Goyal J, Matson M, Marbury T, Smith W, Nestorov I, Hung S.

J Clin Pharmacol. 2015 Feb;55(2):179-88. doi: 10.1002/jcph.390. Epub 2014 Sep 23.

18.

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P.

Antimicrob Agents Chemother. 2014 Nov;58(11):6471-6. doi: 10.1128/AAC.03431-14. Epub 2014 Aug 18.

19.

Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.

Lawitz E, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M.

Antivir Ther. 2015;20(7):699-708. doi: 10.3851/IMP2845. Epub 2014 Aug 8.

PMID:
25105516
20.

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function.

He P, Kerr D, Marbury T, Ries D, Farwell W, Stecher S, Dong Y, Wei D, Rogge M.

J Clin Pharmacol. 2014 Dec;54(12):1383-90. doi: 10.1002/jcph.353. Epub 2014 Jul 3.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk